Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Tong, Qiang ^a   Cai, Qing ^a   De Mooij, Tristan ^b   Xu, Xia ^a   Dai, Shengming ^a   Qu, Wenchun ^b   Zhao, Dongbao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; INFLIXIMAB; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR ALPHA RECEPTOR II IMMUNOGLOBULIN G FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; ETANERCEPT; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ABSCESS; ADULT; ADVERSE DRUG REACTION; ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; CHINA; CHINESE; CONSTIPATION; CONTROLLED STUDY; DISEASE DURATION; DRUG SAFETY; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; ERYTHRODERMA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OTITIS MEDIA; PAPILLEDEMA; PATIENT MONITORING; PNEUMONIA; PREVALENCE; PROTEIN BLOOD LEVEL; PRURITUS; RASH; SKIN ALLERGY; THORAX PAIN; THRUSH; TUBERCULOSIS; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SPONDYLITIS, ANKYLOSING;

ADULT; ANTIRHEUMATIC AGENTS; CHINA; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928880653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119897     Document Type: Article

References (31)

1. Dillon CF, Hirsch R. The United States National Health and Nutrition Examination Survey and the Epidemiology of Ankylosing Spondylitis in the United States: Am J Med Sci 2011;341:281-3 doi: 10.1097/MAJ.0b013e31820f8c83 PMID: 21358307
2. Bakland G, Gran JT, Becker-Merok A, Nordvåg BY, Nossent JC. Work disability in patients with ankylosing spondylitis in Norway. J Rheumatol 2011;38:479-84 doi: 10.3899/jrheum.100686 PMID: 21285159
3. Guellec D, Nocturne G, Tatar Z, Pham T, Sellam J, Cantagrel A, et al. Should non-steroidal antiinflammatory drugs be used continuously in ankylosing spondylitis? Joint Bone Spine. 2014 Jul;81-(4):308-12. doi: 10.1016/j.jbspin. 2014.01.003 PMID: 24589253
4. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, Van Der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Nov. 23; 382(9906):1705-13 doi: 10.1016/S0140-6736 (13) 61134-4 PMID: 24035250
5. Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther. 2011 May 25; 13 Suppl 1:S4 doi: 10.1186/1478-6354-13-S1-S4 PMID: 21624183
6. Braun J, Van Der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of Etanercept versus sulfasalazine in ankylosing spondylitis patients: A randomized, double-blind study (ASCEND Trial). Arthritis Rheum 2011;63:1543-51 doi: 10.1002/art.30223 PMID: 21630245
7. Callhoff J, Sieper J, Weis A, Zink A, Listing J. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axials pondyloarthritis: a meta-analysis. Ann Rheum Dis. 2014 Apr. 9.
8. Tong Q, Zhao DB, Bajracharya P, Xu X, Kong RN, Zhang J, et al. TNF-α-857 and-1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis. Pharmacogenomics. 2012, 13, 1459-1467 doi: 10.2217/pgs.12.133 PMID: 23057546
9. Radstake TR, Svenson M, Eijsbouts AM, Van Den Hoogen FH, Enevold C, Van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functionaldrug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009 Nov; 68(11):1739-45 doi: 10.1136/ard. 2008.092833 PMID: 19019895
10. Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006;8(4):R131 PMID: 16869978
11. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010 May;65-(5):657-61 doi: 10.1111/j.1398-9995.2009.02280.x PMID: 19951375
12. Eudy A, Vines A, Dooley M, Cooper G, Parks C. Elevated C-reactive protein and self-reported disease activity in systemic lupus erythematosus. Lupus. 2014 Jul. 23. pii: 0961203314543915. [Epub ahead of print] PubMed PMID: 25057037
13. Van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr; 27(4):361-8 PMID: 6231933
14. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 published May 28 2009. National Cancer Institute, U. S. National Institutes of Health.
15. Tong Q, Zhao L, Qian XD, Zhang LL, Xu X, Dai SM, et al. Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a metaanalysis. Pharmacogenomics. 2013 Nov; 14(14):1691-700. doi: 10.2217/pgs.13.146 PMID: 24192118
16. Callhoff J, Sieper J, Weis A, Zink A, Listing J. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2014 Apr. 9.
17. Nagy G, Lukacs K, Sziray A, Fazekas K, Florian A, Tamasi L, et al. Adverse events during biological therapy-focusing on dermatological side-effects. Orv Hetil 2011;152(6):212-20 doi: 10.1556/OH.2011. 28987 PMID: 21278026
18. Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 2010;257:1421-31 doi: 10.1007/s00415-010-5591-7 PMID: 20495815
19. Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, et al. Sustained efficacy and safety, including patient-reported outcomes, with Etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:238-45 PMID: 20483046
20. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007 Mar; 156(3):486-91. PMID: 17300238
21. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012 Aug; 29(8):664-74. doi: 10. 1007/s12325-012-0037-5 PMID: 22886712
22. Huang F, Zhang LY, Zhang JL, Zhang FC, Liang DF, Deng XH, et al. A short-term efficacy and safety study of infliximab in active ankylosing spondylitis. Zhonghua Nei Ke Za Zhi. 2006 Feb; 45(2):122-6 PMID: 16624120
23. Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 2009;48:761-4 doi: 10.1093/rheumatology/kep083 PMID: 19395543
24. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52 PMID: 17981916
25. De Moraes JC, Aikawa NE, Ribeiro AC, Saad CG, Carvalho JF, Pereira RM, et al. Immediate complications of 3, 555 injections of anti-TNFα. Rev Bras Reumatol 2010;50:165-75 PMID: 21125152
26. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76 PMID: 16868999
27. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. The infectious profiles of antitumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. Int J Rheum Dis 2009;12(2):118-24 doi: 10.1111/j.1756-185X.2009.01393.x PMID: 20374328
28. Baeten D, Kruithof E, Van Den Bosch F, Van Den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62-(9):829-34 PMID: 12922954
29. Peisajovich A, Marnell L, Mold C, Du Clos TW. C-reactive protein at the interface between innate immunity and inflammation. Expert Rev Clin Immunol. 2008 May; 4(3):379-90 doi: 10.1586/1744666X.4.3. 379 PMID: 20476927
30. Russell AI, Cunningham E, Graham DS, Shepherd C, Roberton CA, Whittaker J, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet. 2004 Jan 1; 13(1):137-47 PMID: 14645206
31. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the BathAnkylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec; 21(12):2286-91 PMID: 7699630